Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan

Summary Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the duration that is effective in preventing a second hip fracture. Our study demonstrated that risk can be reduced when the prescription is ≥ 6 months for the year following...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2020-08, Vol.31 (8), p.1555-1563
Main Authors: Chen, Y.J., Kung, P.T., Chou, W.Y., Tsai, W.C.
Format: Article
Language:English
Subjects:
Alendronate - therapeutic use
Alendronic acid
Bisphosphonates
Bone Density Conservation Agents - therapeutic use
Cohort analysis
Cohort Studies
Endocrinology
Female
Fractures
Health risk assessment
Hip
Hip Fractures - epidemiology
Hip Fractures - etiology
Hip Fractures - prevention & control
Humans
Medicine
Medicine & Public Health
Original Article
Orthopedics
Osteoporosis
Population studies
Population-based studies
Retrospective Studies
Rheumatology
Taiwan - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the duration that is effective in preventing a second hip fracture. Our study demonstrated that risk can be reduced when the prescription is ≥ 6 months for the year following the index hip fracture. Introduction Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the accurate medication possession ratio (MPR) that is effective in preventing a second hip fracture. Our objective was to compare the risk of second hip fracture in patients treated with different MPR of alendronate. Methods In this population-based cohort study, data from National Health Insurance Research Database of Taiwan were analyzed. Patients 50 years and older who had an index hip fracture and were not receiving any osteoporotic medications before their fracture during 2000–2010 were included. The cohort consisted of 88,320 patients who were new alendronate users ( n  = 9278) and non-users ( n  = 79,042). Those without alendronate were matched 4:1 as the control group. Patients were subdivided into those with no medication, MPR
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-020-05399-9